Citations

Mayo Clinic

Clear

354 citation(s) found for "Ny, Lars".

Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Kwon-Chung, Kyung J , Nguyen, M Hong , Palavecino, Elizabeth , Pancholi, Preeti , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Roilides, Emmanuel , Wengenack, Nancy L , Wiederhold, Nathan , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Ahmed, Sarah A , Luethy, Paul , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Gräser, Yvonne , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Leal, Sixto M. , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Wiederhold, Nathan P. , Zhang, Sean X.

Journal of Clinical Microbiology | March 5, 2024 | Volume: 62 | Issue: 4 | Pages: No page available

10.1128/jcm.01625-23 | PMID 38441056 Get It

Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes
Voigt, Jens Hohwü , Pedersen, Steen B. , Møller, Niels , Jessen, Niels , Man, Chiara Dalla , Gormsen, Lars Christian , Søndergaard, Esben , LAURENTI, MARCELLO C. , Dalla Man, Chiara , Møller, Niels , Lauritsen, Katrine Meyer , Hansen, Troels Krarup , Vella, Adrian

Basic & Clinical Pharmacology & Toxicology | February 27, 2024 | Volume: 134 | Issue: 5 | Pages: 643-656

10.1111/bcpt.13991 | PMID 38409617 Get It

AbstractAimsSodium glucose co‐transporter‐2 (SGLT2) inhibition lowers glucose levels independently of insulin, leading to reduced insulin secretion and increased lipolysis, resulting in elevated circulating free fatty acids (FFAs). While SGLT2 inhibition improves tissue insulin sensitivity, the increase in circulating FFAs could reduce insulin sensitivity in skeletal muscle and the liver. We aimed to investigate the effects of SGLT2 inhibition on substrate utilization in skeletal muscle and the liver and to measure beta‐cell function and glucose tolerance.MethodsThirteen metformin‐treated individuals with type 2 diabetes were randomized to once‐daily empagliflozin 25 mg or placebo for 4 weeks in a crossover design. Skeletal muscle glucose and FFA uptake together with hepatic tissue FFA uptake were measured using [18F]FDG positron emission tomography/computed tomography (PET/CT) and [11C]palmitate PET/CT. Insulin secretion and action were estimated using the oral minimal model.ResultsEmpagliflozin did not affect glucose (0.73 ± 0.30 vs. 1.16 ± 0.64, μmol/g/min p = 0.11) or FFA (0.60 ± 0.30 vs. 0.56 ± 0.3, μmol/g/min p = 0.54) uptake in skeletal muscle. FFA uptake in the liver (21.2 ± 10.1 vs. 19 ± 8.8, μmol/100 ml/min p = 0.32) was unaffected.Empagliflozin increased total beta‐cell responsivity (20 ± 8 vs. 14 ± 9, 10−9 min−1, p < 0.01) and glucose effectiveness (2.6 × 10−2 ± 0.3 × 10−2 vs. 2.4 × 10−2 ± 0.3 × 10−2, dL/kg/min, p = 0.02).ConclusionsDespite improved beta‐cell function and glucose tolerance, empagliflozin does not appear to affect skeletal muscle FFA or glucose uptake.
Building Authentic Connection in the Patient-Physician Relationship
Fuehrer, Sheryl, Weil, Amy , Osterberg, Lars , Meunier, Matthew R. , Schwartz, Rachel , Schwartz, Rachel , Zulman, Donna M.

Journal of Primary Care & Community Health | January 28, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319231225996 | PMID 38281122 Get It

Introduction/Objectives: Delivering optimal patient care is impacted by a physician’s ability to build trusting relationships with patients. Identifying techniques for rapport building is important for promoting patient-physician collaboration and improved patient outcomes. This study sought to characterize the approaches highly skilled primary care physicians (PCPs) use to effectively connect with diverse patients. Methods: Using an inductive thematic analysis approach, we analyzed semi-structured interview transcripts with 10 PCPs identified by leadership and/or colleagues for having exceptional patient communication skills. PCPs practiced in 3 diverse clinic settings: (1) academic medical center, (2) Veterans Affairs clinic, and (3) safety-net community clinic. Results and Conclusions: The thematic analysis yielded 5 themes that enable physicians to establish connections with patients: Respect for the Patient, Engaged Curiosity, Focused Listening, Mutual Participation, and Self-Awareness. Underlying all of these themes was a quality of authenticity, or a state of symmetry between one’s internal experience and external words and actions. Adopting these communication techniques while allowing for adaptability in order to remain authentic in one’s interactions with patients may facilitate improved connection and trust with patients. Encouraging physician authenticity in the patient-physician relationship supports a shift toward relationship-centered care. Additional medical education training is needed to facilitate authentic connection between physicians and patients.
Risk of 30-Day All-Cause Readmission in Interstitial Lung Disease Patients after COVID-19: National-Level Data
Zadeh, Ali Vaeli , Dinparastisaleh, Roshan , Vaezi, Atefeh , Bandyopadhyay, Debabrata , Rubinstein, Israel , Baig, Hassan , Kawasaki, Takeshi , Magnusson, Jesper , Larsson, Lars-Olof, Herazo‐Maya, Jose D. , Lee, Augustine S. , Mirsaeidi, Mehdi , Baig, Hassan Z, Kawasaki, Takeshi , Mirsaeidi, Mehdi , Candelario, R.A. Calderon , Shahraki, Abdolrazagh Hashemi , Sharafkhaneh, Amir

Annals of the American Thoracic Society | December 22, 2023 | Volume: 21 | Issue: 3 | Pages: 428-437

10.1513/annalsats.202305-491oc | PMID 38134434 Get It

Abstract Rationale Hospital readmission within 30 days poses challenges for healthcare providers, policymakers, and patients because of its impact on care quality, costs, and outcomes. Patients with interstitial lung disease (ILD) are particularly affected by readmission, which is associated with increased morbidity and mortality and reduced quality of life. Because small sample sizes have hindered previous studies, this study seeks to address this gap in knowledge by examining a large-scale dataset. Objective To determine the rate and probability of 30-day all-cause readmission and secondary outcomes in patients with coronavirus disease (COVID-19) or ILD admitted to the hospital. Methods This study is a nested cohort study that used the PearlDiver patient records database. Adult patients (age ⩾18 yr) who were admitted to hospitals in 28 states in the United States with COVID-19 or ILD diagnoses were included. We defined and analyzed two separate cohorts in this study. The first cohort consisted of patients with COVID-19 and was later divided into two groups with or without a history of ILD. The second cohort consisted of patients with ILD and was later divided into groups with COVID-19 or with a non–COVID-19 pneumonia diagnosis at admission. We also studied two other subcohorts of patients with and without idiopathic pulmonary fibrosis within the second cohort. Propensity score matching was employed to match confounders between groups. The Kaplan-Meier log rank test was applied to compare the probabilities of outcomes. Results We assessed the data of 2,286,775 patients with COVID-19 and 118,892 patients with ILD. We found that patients with COVID-19 with preexisting ILD had an odds ratio of 1.6 for 30-day all-cause readmission. Similarly, an odds ratio of 2.42 in readmission rates was observed among hospitalized individuals with ILD who contracted COVID-19 compared with those who were hospitalized for non–COVID-19 pneumonia. Our study also found a significantly higher probability of intensive care admission among patients in both cohorts. Conclusions Patients with ILD face heightened rates of hospital readmissions, particularly when ILD is combined with COVID-19, resulting in adverse outcomes such as decreased quality of life and increased healthcare expenses. It is imperative to prioritize preventive measures against COVID-19 and establish effective postdischarge care strategies for patients with ILD.
Abstract 14527: AI-ECG is a Cost-Effective Early Screening Tool for Heart Failure With Reduced Ejection Fraction
Sobiesk, Matthew, Hegstrom, Lars , Rincón-Hekking, John , Friedman, Paul A. , Ardhanari, Sankar , Barve, Rakesh , Pawlowski, Colin , López-Jiménez, Francisco , Kapa, Suraj , Attia, Zachi I. , Soundararajan, Venky , Awasthi, Samir

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.14527 Get It

Background: Early diagnosis of heart failure with reduced ejection fraction (HFrEF) can lead to reduced healthcare costs and improved outcomes. In this study, we evaluated the economic effectiveness of an AI algorithm for detecting low ejection fraction using 12-lead ECG data. Aims: The primary aim was to estimate the health economic impact of the AI-ECG algorithm intervention to detect low ejection fraction. Methods: The study population consisted of 113,719 individuals without a prior history of HFrEF who visited a multistate health system between 2010-2018 with 12-lead ECG data and an echocardiogram within 1 year. The AI-ECG algorithm was run retrospectively, and projected costs were estimated assuming each patient incurred the average cost based on their age group and AI-detected heart failure stage. Hospitalization costs were estimated using Medicare reimbursement rates, and economic benefits from increased survival were estimated using a willingness to pay of $50,000 per quality-adjusted life year (QALY) gained. Results: At the optimal model threshold, the total cost savings per patient (including benefits from QALYs gained) for the AI-ECG algorithm vs. standard-of-care on the overall study population were projected to be $79.11 (95% CI: [$53.77, $104.44]) and $124.93 (95% CI: [$83.99, $165.88]) for the 2 and 4 year periods, respectively. For patients over 50 years old, the projected total cost savings were $85.56 (95% CI: [$56.35, $114.78]) and $135.28 (95% CI: [$88.18, $182.38]) per patient for the 2 and 4 year periods, respectively. See Figure. Conclusions: The AI-ECG algorithm to detect low ejection fraction is a cost-effective early screening tool for HFrEF.
International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts
Timmins, Iain R. , Jones, Michael E. , O’Brien, Katie M. , Adami, Hans‐Olov , Aune, Dagfinn , Brantley, Kristen D. , Chen, Yu , DeHart, Jessica Clague , Clendenen, Tess V. , Fournier, A. , Hankinson, Susan E. , Houlston, Richard S. , Kirsh, Victoria A. , Linet, Martha S. , May, Anne M. , Rohan, Thomas E. , Ruddy, Kathryn J. , Sund, Malin , Vachon, Celine M. , Vatten, Lars J. , Visvanathan, Kala , Yuan, Jian‐Min , Zheng, Wei , Nichols, Hazel B. , Baglietto, Laura , Bertrand, Kimberly A , Brantley, Kristen D , Clague DeHart, Jessica , Clendenen, Tess V , Dossus, Laure , Eliassen, A Heather , Fletcher, Olivia , Fournier, Agnès , Håkansson, Niclas , Houlston, Richard S , Joshu, Corinne E , Kirsh, Victoria A , Kitahara, Cari M , Linet, Martha S , Park, Hannah Lui , Lynch, Brigid M , May, Anne M , Mellemkjær, Lene , Milne, Roger L , Palmer, Julie R , Ruddy, Kathryn J , Sánchez, Maria-Jose , Shu, Xiao-Ou , Steindorf, Karen , Sund, Malin , Vachon, Celine M. , Vatten, Lars J , Visvanathan, Kala , Weiderpass, Elisabete , Willett, Walter C , Wolk, Alicja , Zheng, Wei , Nichols, Hazel B , Sandler, Dale P , Jones, Michael E , O'Brien, Katie M , Aune, Dagfinn , Chen, Yu , Baglietto, Laura , Bertrand, Kimberly A. , Eliassen, A. Heather , Fletcher, Olivia , Håkansson, Niclas , Hankinson, Susan E. , Kitahara, Cari M. , Koh, Woon‐Puay , Milne, Roger L. , Palmer, Julie R. , Ricceri, Fulvio , Sánchez, María‐José , Shu, Xiao‐Ou , Smith-Byrne, Karl , Weiderpass, Elisabete , Willett, Walter C. , Wolk, Alicja , Sandler, Dale P. , Swerdlow, Anthony J. , Schoemaker, Minouk J.

Journal of Clinical Oncology | December 11, 2023 | Volume: 42 | Issue: 8 | Pages: 927-939

10.1200/jco.23.01101 | PMID 38079601 Get It

PURPOSE There is strong evidence that leisure-time physical activity is protective against postmenopausal breast cancer risk but the association with premenopausal breast cancer is less clear. The purpose of this study was to examine the association of physical activity with the risk of developing premenopausal breast cancer. METHODS We pooled individual-level data on self-reported leisure-time physical activity across 19 cohort studies comprising 547,601 premenopausal women, with 10,231 incident cases of breast cancer. Multivariable Cox regression was used to estimate hazard ratios (HRs) and 95% CIs for associations of leisure-time physical activity with breast cancer incidence. HRs for high versus low levels of activity were based on a comparison of risk at the 90th versus 10th percentiles of activity. We assessed the linearity of the relationship and examined subtype-specific associations and effect modification across strata of breast cancer risk factors, including adiposity. RESULTS Over a median 11.5 years of follow-up (IQR, 8.0-16.1 years), high versus low levels of leisure-time physical activity were associated with a 6% (HR, 0.94 [95% CI, 0.89 to 0.99]) and a 10% (HR, 0.90 [95% CI, 0.85 to 0.95]) reduction in breast cancer risk, before and after adjustment for BMI, respectively. Tests of nonlinearity suggested an approximately linear relationship ( Pnonlinearity = .94). The inverse association was particularly strong for human epidermal growth factor receptor 2–enriched breast cancer (HR, 0.57 [95% CI, 0.39 to 0.84]; Phet = .07). Associations did not vary significantly across strata of breast cancer risk factors, including subgroups of adiposity. CONCLUSION This large, pooled analysis of cohort studies adds to evidence that engagement in higher levels of leisure-time physical activity may lead to reduced premenopausal breast cancer risk.
DPPX Autoantibody: Frequency, Clinical Accompaniments and Outcomes (S40.001)
Lennon, Vanda A. , Komorowski, Lars , Probst, Christian , Clardy, Stacey , Aksamit, Allen J. , Lucchinetti, Claudia F. , Tippmann‐Peikert, Maja, Clardy, Stacey L , Tobin, W. Oliver , Pittock, Sean J. , Wirrell, Elaine , McKeon, Andrew

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s40.001 Get It

Recoverin Antibody: Ophthalmologic & Oncologic Significance (P6.131)
Lopez, Alfonso, Pulido, José S. , Komorowski, Lars , Roforth, Matthew M., Iezzi, Raymond , Meyer, Wolfgang , McKeon, Andrew , Lachance, Daniel Honore , Pittock, Sean J.

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p6.131 Get It

Medusa Head-Type Neuronal Autoantibody Inositol Triphosphate Receptor-1 (ITPR1)-IgG: Frequency, Clinical Phenotype and Cancer Associations (P5.300)
Alfugham, Nora, Lennon, Vanda A. , Komorowski, Lars , Probst, Christian , Scharf, Madeleine, Pittock, Sean J.

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p5.300 Get It

Rho GTPase Activating Protein 26 (ARHGAP26)-Igg Autoimmunity: Frequency and Clinical Associations (P3.346)
Alfugham, Nora, Lennon, Vanda A. , Komorowski, Lars , Probst, Christian , Pittock, Sean J.

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p3.346 Get It